GNS Healthcare Blog

GNS Healthcare Primary Blog

By December 31, 1969

GNS Healthcare Blog

How AI is Aiding Discoveries in Rare Disease Research

The Orphan Drug Act of 1983 defined a rare disease as one that affects less than 200,000 people. According to the NIH National Center for Advancing Translational Sciences, there are now 7,000 such diseases afflicting between 25-30 million people in the U. S. and an estimated 350 million worldwide.

Finding therapies for rare diseases not only helps those affected, but according to studies from the NIH Undiagnosed Diseases Program, new discoveries made from studying these diseases can also provide insights into more common conditions.

At Alexion, we are interested in understanding the rare...

Read More

Are value-based contracts the end of the journey or just a stop along the way?

The drive to value-based care has become a significant issue for biopharma companies as more health plans request value-based contracts. According to McKinsey, over 200 of these innovative contracts have been publicly disclosed since 1994¹. The buzz around the biopharma industry is that these value-based contracts are the wave of the future. Although this trend is likely to continue in the immediate future, the shift to these types of contracts may not survive in the long term. Precision medicine may make them obsolete.

 

Types of innovative biopharma contracts

The two most prevalent types...

Read More

Taking the Plunge: From ALS Ice Bucket Challenge to ALS Research with AI and Robust Data

If you drove around Boston in the summer of 2014, you wouldn’t be surprised to see individuals on their lawns, driveways, or in their back yards dumping buckets of ice water over their heads. The chilly act was part of a challenge that encouraged participants to film their icy shower, post it to social media, and nominate others to do the same. The nominee had 24 hours to comply or donate money to The ALS Association. Most people did both and the videos went viral, spreading across the country and, eventually, the world.

The ALS Ice Bucket Challenge was the brainchild of former Boston...

Read More

Optimizing Drug R&D: 3 Strategies to Embrace

Biopharma continues to look for ways to streamline the drug development process. With costs of bringing a drug to market now reaching $2.7 billion and the timeline stretching to nearly a decade, stakeholders across the healthcare continuum are clamoring for a faster, less expensive method. 

The drug research and development process is well established and has remained largely unchanged over the past few decades and for good reason – it works. The methodology biopharma has followed has given the world many effective drugs which are both improving the quality of life for patient as well as...

Read More

Data and AI Taking Center Stage at BIO 2018

“AI is your rocket ship and data is the fuel."

Michael Dell said this to customers and partners at his annual conference, but the message will be one of the key takeaways for the 16,000 attendees expected at the 2018 BIO International Convention to be held in Boston next week. More than 5,000 companies from 70 different countries will be represented at the gathering that brings together biotechnology and pharma leaders for a week of intensive networking to discover new opportunities and promising partnerships. Discussions cover a wide spectrum of life science and application areas...

Read More

Subscribe to the GNS Blog

Recent Posts:

Twitter